Currently, several biomarkers have been identified that predict patient response to immunotherapy, such as PD-L1, TMB (tumor mutational burden), GEP (gene expression profiles), TILs (tumor infiltration lymphocytes) and PD-L2 [30]. Here, CD274 is linked to neoplasm.